CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2093-2104

  Pecora, Andrew L ^a   Preti, Robert A ^a   Gleim, Gilbert W ^a   Jennis, Andrew ^a   Zahos, Kathleen ^a   Cantwell, Susan ^a   Doria, Lisa ^a   Isaacs, Randi ^a   Gillio, Alfred P ^a   Michelis, Mary Ann ^a   Brochstein, Joel A ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD TRANSFUSION; CELL POPULATION; CELL SUBPOPULATION; CHILD; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE TRANSFUSION;

EID: 0031801996     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2093     Document Type: Article

References (44)

1. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991
2. Hartmann O, Gaelle Le Corroller A, Biaise D, et al: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. Ann Intern Med 126:600-607, 1997
3. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncl 13:2547-2555, 1995
4. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment kinetics as a function of the CD34 content of peripheral-blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 10:3961-3969, 1995
5. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
6. Chao NJ, Shriber JR, Grimes K, et al: Granulocyte colony-stimulating factor "mobilized" peripheral-blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031-2035, 1993
7. Watts MJ, Sullivan AM, Jamieson E, et al: Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 15:535-546, 1997
8. Demirer T, Buckner CD, Storer B, et al: Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor: J Clin Oncl 15:684-690, 1997
9. Schwartzberg LS: Peripheral-blood stem cell mobilization in the out-patient setting, in Wunder EW, Henon PR (eds): Peripheral Blood Stem Cell Autografts. Heidelberg, Germany, Springer-Verlag, 1993, pp 177-186
10. Smith TJ, Hillner BE, Schmitz N, et al: Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncl 15:5-10, 1997
11. To LB, Roberts MM, Haylock DN, et al: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277-284, 1992
12. Andrews RG, Singer JW, Bernstein ID: Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of CD33 and CD34 antigens and light scatter properties. J Exp Med 169:1721-1731, 1989
13. Krause DS, Fackler MJ, Civin CI, et al: CD34: Structure, biology, and clinical utility. Blood 87:1-13, 1996
14. Berardi AC, Wang A, Levine JD, et al: Functional isolation and characterization of human hematopoietic stem cells. Science 267:104-108, 1995
15. Bender JG, Unverzagt KL, Walker DE, et al: Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 77:2591-2596, 1991
16. Bender JG, Williams SF, Myers S, et al: Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. Bone Marrow Transplant 10:281-285, 1992
17. Dercksen MW, Rodenhuis S, Dirkson MKA, et al: Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem cell transplantation. J Clin Oncl 13:1922-1932, 1995
18. Copelan EA, Ceselski SK, Ezzone SA, et al: Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncl 15:759-765, 1997
19. Weaver A, Ryder D, Crowther D, et al: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 88:3323-3328, 1996
20. Sutherland DR, Keating A, Nayar R, et al: Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Haematol 22:1003-1010, 1994
21. Serke S, Sauberlich S, Huhn D: Multiparameter flow-cytometrical quantitation of circulating CD34+-cells: Correlation to the quantitation of circulating haemopoietic progenitor cells by in vitro colony-assay. Br J Haematol 77:453-459, 1991
22. Zimmerman TM, Lee WJ, Bender JG, et al: Quantitative CD34 analysis may be used to guide peripheral-blood stem cell harvest. Bone Marrow Transplant 9:439-444, 1995
23. Pecora AL, Brochstein JA, Jennis A, et al: Total CD34+ cell content and CD34+CD33- subset predict time to neutrophil and platelet engraftment and hospital discharge in patients following high-dose chemotherapy (HDC) with primed peripheral blood progenitor cells (PBPC). Blood 84:88A, 1994 (abstr: suppl)
24. Tricot G, Jagannath S, Vesole D, et al: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596, 1995
25. To LB, Haylock DN, Simmons PJ, et al: The biology and clinical use of blood stem cells. Blood 89:2233-2258, 1997
26. Sutherland, DR, Anderson L, Keeney M, et al: The ISHAGE guidelines for CD34+ Cell Determination by flow cytometry. J Hematother 5:213-226, 1996
27. Rosenfeld CS, Cullis H, Tarosky T, et al: Peripheral blood stem cell collection using the small volume collection chamber in the Fenwal CS-3000 plus blood cell separator. Bone Marrow Transplant 9:277-284, 1992
28. Stiff PJ, Koester AR, Weidner MK, et al: Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled rate freezing. Blood 70:974-979, 1987
29. Schneider JG, Crown JP, Wasserheit C, et al: Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transplant 14:877-884, 1994
30. Chabannon C, Le Coroller AG, Faucher C, et al: Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 4:171-179, 1995
31. Shimazaki C, Yamagata N, Tatsumi T, et al: Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: Factors affecting progenitor cell yields. Bone Marrow Transplant 15:763-767, 1995
32. To LB, Haylock DN, Dowse T, et al: A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB ad bone marrow CD34+ cells. Blood 84:2930-2939, 1994
33. Kotasek D, Shepherd KM, Sage RE, et al: Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9:11-17, 1992
34. Haas R, Mohle R, Murea S, et al: Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant granulocyte colony-stimulating factor. J Hematother 3:323-330, 1994
35. Jennis A, Pecora AL, Isaacs RE, et al: Dose-intensive cyclophosphamide, etoposide, and platinum (DICEP) as a priming/mobilization regimen for peripheral blood stem cell (PBSC) harvesting prior to high dose chemotherapy (HDC). Blood 88:404A, 1996 (abstr; suppl)
36. Bolwell BJ, Fishleder A, Andresen SW, et al: G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment. Bone Marrow Transplant 12:609-614, 1993
37. Dreger P, Kloss M, Petersen B, et al: Autologous progenitor cell transplantation: Prior exposure to stem cell toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86:3970-3978, 1995
38. Reiffers J, Faberes C, Boiron JM, et al: Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: Analysis of factors affecting the rate of engraftment. J Hematother 3:185-191, 1994
39. To LB, Haylock DN, Dyson PG, et al: An unusual pattern of haemopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 6:109-117, 1990
40. Uchida N, Dongping H, Friera AM, et al: The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood 89:465-472, 1997
41. Moskowitz CH, Stiff P, Gordon MS, et al: Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - Results of a phase I/II trial. Blood 89:3136-3147, 1997
42. Somlo G, Sniecinski I, Odom-Maryon T, et al: Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood 89:1521-1528, 1997
43. Haylock DN, To LB, Dowse TL, et al: Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 80:1405-1412, 1992
44. Bender JG, To LB, Williams S, et al: Defining a therapeutic dose of peripheral blood stem cells. J Hermatother 1:329-341, 1992